Brief: Edgewise Therapeutics Inc Receives EMA Orphan Drug Designations For Sevasemten
23/04/2024 13:36
April 23 (Reuters) - Edgewise Therapeutics Inc EWTX.O :
* EDGEWISE THERAPEUTICS INC - EMA ORPHAN DRUG DESIGNATIONS
FOR
SEVASEMTEN (EDG-5506) FOR TREATMENT OF BECKER AND DUCHENNE
MUSCULAR DYSTROPHIES
Source text for Eikon: ID:nBw6qSfgca
Further company coverage: EWTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edgewise Therapeutics
See all newsBrief: Edgewise Therapeutics Doses First Patient In Phase 2 Equinox-Hfpef Trial Of Edg-15400
Edgewise Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Edgewise Therapeutics Q2 net loss widens on higher expenses
Brief: Edgewise Therapeutics Q2 Operating Income USD -61.943 Million
U.S. STOCKS ON THE MOVE-RBB Bancorp, Roblox, Open Lending